AI-driven biopharma firm BioXcel Therapeutics posts lower-than-expected Q4 loss on reduced SG&A costs

BioXcel Therapeutics

27/03/2026 11:11

Overview

U.S. neuroscience drugmaker's Q4 revenue beat analyst expectations despite year-over-year decline

Q4 basic EPS loss was narrower than analysts expected

Outlook

BioXcel Therapeutics continues to progress its Alzheimer's dementia program as part of broader strategy

Result Drivers

CLINICAL TRIAL SPENDING - Increased R&D expenses driven by SERENITY At-Home pivotal Phase 3 safety trial

LOWER SG&A COSTS - SG&A expenses declined due to reduced personnel, legal, and commercial costs from clinical reprioritization

Company press release: ID:nGNX18M597

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Revenue
Beat
$256,000
$162,000 (5 Analysts)
Q4 Net Income
Beat
-$12.55 mln
-$14.42 mln (4 Analysts)
Q4 Basic EPS
Beat
-$0.58
-$0.75 (4 Analysts)
Q4 Operating Income
Beat
-$10.28 mln
-$11.70 mln (5 Analysts)
Q4 Operating Expenses
$10.54 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", no "hold" and 1 "sell" or "strong sell"

Wall Street's median 12-month price target for BioXcel Therapeutics Inc is $12.00, about 775.9% above its March 26 closing price of $1.37

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)